Wuhan Healthgen Biotechnology (688765) Stock Overview
Engages in the research and development of molecular pharmaceuticals in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
688765 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Wuhan Healthgen Biotechnology Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥83.19 |
| 52 Week High | CN¥132.03 |
| 52 Week Low | CN¥73.33 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688765 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -11.0% | 4.1% | -0.5% |
| 1Y | n/a | 10.6% | 21.5% |
Return vs Industry: Insufficient data to determine how 688765 performed against the CN Biotechs industry.
Return vs Market: Insufficient data to determine how 688765 performed against the CN Market.
Price Volatility
| 688765 volatility | |
|---|---|
| 688765 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 9.3% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688765's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: Insufficient data to determine 688765's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 158 | Daichang Yang | www.oryzogen.com |
Wuhan Healthgen Biotechnology Corp. engages in the research and development of molecular pharmaceuticals in China. The company offers recombinant human serum albumin, proteins for cosmetics ingredients, and other recombinant proteins. It also provides recombinant growth factors, such as recombinant human epidermal growth factor, recombinant human basic fibroblast growth factor, recombinant human insulin-like growth factor-1 LR3, recombinant human vascular endothelial growth factor, recombinant human keratinocyte growth factor, recombinant human fibronectin, recombinant human a-1 antitrypsin, recombinant human lactoferrin, recombinant human epidermal growth factor, and recombinant human fibronectin.
Wuhan Healthgen Biotechnology Corp. Fundamentals Summary
| 688765 fundamental statistics | |
|---|---|
| Market cap | CN¥30.75b |
| Earnings (TTM) | -CN¥154.40m |
| Revenue (TTM) | CN¥28.39m |
Is 688765 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688765 income statement (TTM) | |
|---|---|
| Revenue | CN¥28.39m |
| Cost of Revenue | CN¥10.19m |
| Gross Profit | CN¥18.21m |
| Other Expenses | CN¥172.61m |
| Earnings | -CN¥154.40m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 64.12% |
| Net Profit Margin | -543.81% |
| Debt/Equity Ratio | 91.5% |
How did 688765 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/17 08:27 |
| End of Day Share Price | 2025/11/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Wuhan Healthgen Biotechnology Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.